$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000155837024003161 Filed on March 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$3.748M	$10.49M	$65.49M
YoY Change	-60.91%	21.65%	37.48%
Cost Of Revenue	$2.602M	$8.856M	$22.98M
YoY Change	-15.66%	269.0%	17.3%
Gross Profit	$1.146M	$1.630M	$42.51M
YoY Change	-82.38%	-73.79%	51.58%
Gross Profit Margin	30.58%	15.54%	64.91%
Selling, General & Admin	$3.115M	$4.143M	$14.96M
YoY Change	0.0%	33.65%	27.73%
% of Gross Profit	271.82%	254.17%	35.19%
Research & Development	$2.887M	$3.102M	$17.09M
YoY Change	-50.62%	-44.8%	-41.76%
% of Gross Profit	251.92%	190.31%	40.21%
Depreciation & Amortization	$322.0K	$313.0K	$1.200M
YoY Change	15.0%	11.79%	9.09%
% of Gross Profit	28.1%	19.2%	2.82%
Operating Expenses	$6.002M	$7.245M	$32.05M
YoY Change	-33.03%	-16.82%	-21.94%
Operating Profit	-$4.856M	-$5.615M	$10.46M
YoY Change	97.48%	125.5%	-180.37%
Interest Expense	$123.0K	-$811.0K	-$1.515M
YoY Change	-125.63%	12.64%	15.65%
% of Operating Profit			-14.48%
Other Income/Expense, Net	$123.0K		-$1.894M
YoY Change	-125.79%		36.95%
Pretax Income	-$4.733M	-$6.426M	$8.566M
YoY Change	61.21%	100.19%	-159.5%
Income Tax	-$138.0K	-$382.0K	$254.0K
% Of Pretax Income			2.97%
Net Earnings	-$4.595M	-$6.044M	$8.312M
YoY Change	46.76%	61.6%	-155.68%
Net Earnings / Revenue	-122.6%	-57.64%	12.69%
Basic Earnings Per Share	-$0.06		$0.12
Diluted Earnings Per Share	-$0.06	-$0.08	$0.09
COMMON SHARES
Basic Shares Outstanding	73.05M	72.95M	67.51M
Diluted Shares Outstanding	73.04M		82.42M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.21M	$23.63M	$23.63M
YoY Change	-17.55%	38.21%	38.21%
Cash & Equivalents	$27.21M	$23.63M	$23.63M
Short-Term Investments
Other Short-Term Assets	$812.0K	$1.055M	$21.98M
YoY Change	7.12%	-19.47%	243.45%
Inventory	$22.35M	$19.05M	$19.05M
Prepaid Expenses		$444.0K
Receivables	$3.759M	$5.272M	$5.272M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$75.40M	$69.93M	$69.93M
YoY Change	36.11%	55.82%	55.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.781M	$4.973M	$10.88M
YoY Change	1.64%	9.22%	13.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.761M	$3.620M	$3.620M
YoY Change	189.31%	178.46%	178.46%
Total Long-Term Assets	$14.42M	$14.50M	$14.50M
YoY Change	29.24%	32.96%	33.05%
TOTAL ASSETS
Total Short-Term Assets	$75.40M	$69.93M	$69.93M
Total Long-Term Assets	$14.42M	$14.50M	$14.50M
Total Assets	$89.83M	$84.43M	$84.43M
YoY Change	34.96%	51.35%	51.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.77M	$19.55M	$4.320M
YoY Change	268.04%	59.32%	-26.78%
Accrued Expenses	$8.451M	$9.009M	$12.37M
YoY Change	668.27%	12.5%	11.41%
Deferred Revenue	$11.04M	$0.00
YoY Change	-6.37%	-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.42M	$20.25M	$20.25M
YoY Change
Total Short-Term Liabilities	$54.83M	$45.53M	$45.53M
YoY Change	73.97%	40.4%	40.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$5.211M	$5.335M	$5.335M
YoY Change	-10.16%	-8.02%	-8.02%
Total Long-Term Liabilities	$5.211M	$5.335M	$5.335M
YoY Change	-84.69%	-84.31%	-84.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$54.83M	$45.53M	$45.53M
Total Long-Term Liabilities	$5.211M	$5.335M	$5.335M
Total Liabilities	$60.04M	$50.87M	$50.87M
YoY Change	-8.41%	-23.43%	-23.4%
SHAREHOLDERS EQUITY
Retained Earnings		-$381.5M
YoY Change		-2.13%
Common Stock		$415.1M
YoY Change		9.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$29.79M	$33.57M	$33.57M
YoY Change
Total Liabilities & Shareholders Equity	$89.83M	$84.43M	$84.43M
YoY Change	34.96%	51.35%	51.32%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.595M	-$6.044M	$8.312M
YoY Change	46.76%	61.6%	-155.68%
Depreciation, Depletion And Amortization	$322.0K	$313.0K	$1.200M
YoY Change	15.0%	11.79%	9.09%
Cash From Operating Activities	$4.188M	$3.595M	-$1.318M
YoY Change	-239.69%	-237.74%	-94.73%
INVESTING ACTIVITIES
Capital Expenditures	$598.0K	$250.0K	$1.149M
YoY Change	141.13%	19.05%	82.96%
Acquisitions
YoY Change
Other Investing Activities	$8.000K	-$92.00K	$142.0K
YoY Change	-60.0%	-101.78%	-123.95%
Cash From Investing Activities	-$606.0K	-$342.0K	-$16.71M
YoY Change	-112.81%	-106.91%	231.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$23.95M
YoY Change			190.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	24.67M
YoY Change	-100.0%	-100.0%	199.42%
NET CHANGE
Cash From Operating Activities	4.188M	3.595M	-1.318M
Cash From Investing Activities	-606.0K	-342.0K	-16.71M
Cash From Financing Activities	0.000	0.000	24.67M
Net Change In Cash	3.575M	3.253M	6.523M
YoY Change	-77.55%	-49.33%	-129.82%
FREE CASH FLOW
Cash From Operating Activities	$4.188M	$3.595M	-$1.318M
Capital Expenditures	$598.0K	$250.0K	$1.149M
Free Cash Flow	$3.590M	$3.345M	-$2.467M
YoY Change	-210.6%	-218.62%	-90.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72952124
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-33357
CY2023	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0643773
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 University Plaza
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Hackensack
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07601
CY2023	dei	City Area Code CityAreaCode	201
CY2023	dei	Local Phone Number LocalPhoneNumber	696-9345
CY2023	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	PLX
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	139300000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73052124
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	Kesselman & Kesselman C.P.A.s
CY2023	dei	Auditor Firm AuditorFirmId	1309
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17111000
CY2023Q4	plx	Short Term Bank Deposits ShortTermBankDeposits	20926000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4586000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5272000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1310000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23634000
CY2022Q4	plx	Short Term Bank Deposits ShortTermBankDeposits	5069000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1055000
CY2022Q4	us-gaap	Inventory Net InventoryNet	16804000
CY2023Q4	us-gaap	Inventory Net InventoryNet	19045000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	44880000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	69932000
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1267000
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	528000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4553000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4973000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3092000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5087000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5909000
CY2022Q4	us-gaap	Assets Assets	55787000
CY2023Q4	us-gaap	Assets Assets	84434000
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5862000
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4320000
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	12271000
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	19550000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1118000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1409000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13178000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	20251000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32429000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45530000
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	28187000
CY2022Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1642000
CY2023Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	714000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4169000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4621000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	33998000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5335000
CY2022Q4	us-gaap	Liabilities Liabilities	66427000
CY2023Q4	us-gaap	Liabilities Liabilities	50865000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	144000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	185000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53790167
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53790167
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72952124
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	54000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	73000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	379167000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	415045000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-389861000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82424016
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-381549000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10640000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	33569000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55787000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	84434000
CY2021	us-gaap	Revenues Revenues	38350000
CY2022	us-gaap	Revenues Revenues	47638000
CY2023	us-gaap	Revenues Revenues	65494000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	16349000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	19592000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	22982000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29734000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29349000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17093000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12729000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11711000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14959000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-20462000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-13014000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	10460000
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	7521000
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2529000
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3180000
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	401000
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1146000
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1286000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7120000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1383000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1894000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27582000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14397000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8566000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	530000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	254000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27582000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14927000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	8312000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44140233
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48472159
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67512527
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44140233
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48472159
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-27037000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37625000
CY2021	plx	Stock Issued During Period Value Sales Agreement StockIssuedDuringPeriodValueSalesAgreement	8575000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1405000
CY2021	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	970000
CY2021	plx	Reacquisition Of Equity Component Of Convertible Notes ReacquisitionOfEquityComponentOfConvertibleNotes	12019000
CY2021	plx	Equity Component Of Convertible Notes Net Of Transaction Costs EquityComponentOfConvertibleNotesNetOfTransactionCosts	12027000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27582000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6036000
CY2022	plx	Stock Issued During Period Value Sales Agreement StockIssuedDuringPeriodValueSalesAgreement	8236000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1124000
CY2022	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	961000
CY2022	plx	Stock Issued During Period Value Warrants Exercises StockIssuedDuringPeriodValueWarrantsExercises	2000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14927000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10640000
CY2023	plx	Stock Issued During Period Value Sales Agreement StockIssuedDuringPeriodValueSalesAgreement	23954000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7783000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1928000
CY2023	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	1520000
CY2023	plx	Stock Issued During Period Value Warrants Exercises StockIssuedDuringPeriodValueWarrantsExercises	712000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	8312000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	33569000
CY2021	us-gaap	Profit Loss ProfitLoss	-27582000
CY2022	us-gaap	Profit Loss ProfitLoss	-14927000
CY2023	us-gaap	Profit Loss ProfitLoss	8312000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2375000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2085000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3448000
CY2021	us-gaap	Depreciation Depreciation	1118000
CY2022	us-gaap	Depreciation Depreciation	1086000
CY2023	us-gaap	Depreciation Depreciation	1191000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-417000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	989000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	446000
CY2021	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	133000
CY2022	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	-543000
CY2023	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	3000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3092000
CY2021	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	100000
CY2022	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	-3000
CY2023	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	50000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	51000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-831000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	plx	Gain Loss On Debt Conversion GainLossOnDebtConversion	0
CY2022	plx	Gain Loss On Debt Conversion GainLossOnDebtConversion	0
CY2023	plx	Gain Loss On Debt Conversion GainLossOnDebtConversion	421000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2673000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	300000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	267000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	13230000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-7162000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13178000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1032000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1194000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	428000
CY2021	plx	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	-241000
CY2022	plx	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	5000
CY2023	plx	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	-13000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4872000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1150000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2241000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2385000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4804000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5295000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-51000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10285000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25000000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1318000
CY2021	plx	Increase Decrease In Bank Deposits IncreaseDecreaseInBankDeposits	37835000
CY2022	plx	Increase Decrease In Bank Deposits IncreaseDecreaseInBankDeposits	16000000
CY2023	plx	Increase Decrease In Bank Deposits IncreaseDecreaseInBankDeposits	20420000
CY2021	plx	Proceeds From Sale Of Short Term Deposits ProceedsFromSaleOfShortTermDeposits	57835000
CY2022	plx	Proceeds From Sale Of Short Term Deposits ProceedsFromSaleOfShortTermDeposits	11000000
CY2023	plx	Proceeds From Sale Of Short Term Deposits ProceedsFromSaleOfShortTermDeposits	5000000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1459000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	628000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1149000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	53000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2021	plx	Increase Decrease In Restricted Deposit IncreaseDecreaseInRestrictedDeposit	-436000
CY2022	plx	Increase Decrease In Restricted Deposit IncreaseDecreaseInRestrictedDeposit	0
CY2023	plx	Increase Decrease In Restricted Deposit IncreaseDecreaseInRestrictedDeposit	0
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	109000
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-593000
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	142000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18921000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5035000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16711000
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	30036000
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4086000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2021	plx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	37625000
CY2022	plx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	0
CY2023	plx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8575000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8236000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23954000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	712000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12078000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8238000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24666000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-77000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-114000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20720000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21874000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6523000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18265000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38985000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17111000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38985000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17111000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23634000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	94000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	143000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	614000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	309000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	794000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1567000
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7783000
CY2023	plx	Partial Settlement Of Liability For Employee Rights Upon Retirement Through Transfer Of Related Funds PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds	882000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3410000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2198000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2742000
CY2021	plx	Interest Received Net InterestReceivedNet	379000
CY2022	plx	Interest Received Net InterestReceivedNet	93000
CY2023	plx	Interest Received Net InterestReceivedNet	355000
CY2023Q4	plx	Number Of Global Licensing And Supply Agreements NumberOfGlobalLicensingAndSupplyAgreements	2
CY2023Q1	plx	Number Of Patients Dosed NumberOfPatientsDosed	56
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c. Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to the assessment of sales reserves and valuation allowances.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m. Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company’s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company’s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December 31, 2022, the accounts receivables balance was composed of $2.3 million from Fiocruz, $1.2 million from Chiesi and $1.1 million from Pfizer, and, as of December 31, 2023, the accounts receivables balance was composed of $0.7 million from Chiesi and $4.6 million from Pfizer.</p>
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	38239000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	39661000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33686000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34688000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4553000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4973000
CY2021	us-gaap	Depreciation Depreciation	1100000
CY2022	us-gaap	Depreciation Depreciation	1100000
CY2023	us-gaap	Depreciation Depreciation	1200000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3508000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4176000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2678000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9055000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10618000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5814000
CY2022Q4	us-gaap	Inventory Net InventoryNet	16804000
CY2023Q4	us-gaap	Inventory Net InventoryNet	19045000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	400000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	40000.00
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	800000
CY2021	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	108000
CY2022	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	96000
CY2023	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	142000
CY2021	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	990000
CY2022	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	945000
CY2023	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	801000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	857000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	800000
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	798000
CY2021	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	100000
CY2022	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	-3000
CY2023	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	50000
CY2023Q4	plx	Number Of Employees To Receive Benefits During Next Five Years NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears	0
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	true
CY2023	plx	Lessee Operating Lease Number Of Renewal Term Extensions LesseeOperatingLeaseNumberOfRenewalTermExtensions	1
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	502000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1632000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1398000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1471000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1391000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1404000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1484000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.128
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.128
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.128
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1409000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1397000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1125000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1044000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4057000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9032000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3002000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6030000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	144000000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	185000000
CY2023Q4	plx	Common Stock Number Of Voting Rights CommonStockNumberOfVotingRights	1
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	633409
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2375000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2085000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3448000
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8749999
CY2021Q1	us-gaap	Share Price SharePrice	4.60
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40200000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27582000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14927000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	8312000
CY2023	us-gaap	Dilutive Securities DilutiveSecurities	-1168000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-27582000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14927000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7144000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44140233
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48472159
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67512527
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	13335430
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1576059
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44140233
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48472159
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82424016
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	530000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3346000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3092000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	530000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	254000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.03
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.04
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q2	plx	Milestone Payment Received MilestonePaymentReceived	20000000.0
CY2023Q2	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3100000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	28500000
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	14400000
CY2023	plx	Capitalized Research And Development Cost Amortization Period CapitalizedResearchAndDevelopmentCostAmortizationPeriod	P15Y
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	234800000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	247400000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6568000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4625000
CY2022Q4	plx	Deferred Tax Assets Other Timing Differences DeferredTaxAssetsOtherTimingDifferences	-2115000
CY2023Q4	plx	Deferred Tax Assets Other Timing Differences DeferredTaxAssetsOtherTimingDifferences	-1387000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54097000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51472000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58550000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51618000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3092000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5792000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3023000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1799000
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1512000
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-899000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	2979000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1684000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5792000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2970000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6932000
CY2022	plx	Effective Income Tax Rate Reconciliation Utilization Of Carry Forward Losses And Other Temporary Items Without Deferred Taxes Recognition EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition	2032000
CY2023	plx	Effective Income Tax Rate Reconciliation Utilization Of Carry Forward Losses And Other Temporary Items Without Deferred Taxes Recognition EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition	3602000
CY2023	plx	Effective Income Tax Rate Reconciliation Withholding Tax EffectiveIncomeTaxRateReconciliationWithholdingTax	-1000000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	530000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	254000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61520000
CY2022	plx	Deferred Tax Assets Valuation Allowance Reductions During Period DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod	2970000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58550000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58550000
CY2023	plx	Deferred Tax Assets Valuation Allowance Additions During Period DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod	728000
CY2023	plx	Deferred Tax Assets Valuation Allowance Reductions During Period DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod	7660000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51618000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	530000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	530000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	530000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	275000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	805000
CY2022Q4	plx	Other Assets Institutions Current OtherAssetsInstitutionsCurrent	364000
CY2023Q4	plx	Other Assets Institutions Current OtherAssetsInstitutionsCurrent	482000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	774000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	444000
CY2022Q4	plx	Other Assets Sundry Current OtherAssetsSundryCurrent	172000
CY2023Q4	plx	Other Assets Sundry Current OtherAssetsSundryCurrent	129000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1310000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1055000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1216000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1437000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	719000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	511000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1404000
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1605000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7478000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9009000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	781000
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	637000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	530000
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2876000
CY2023Q4	plx	Reserve For Deductions From Revenue Current ReserveForDeductionsFromRevenueCurrent	2861000
CY2022Q4	plx	Accounts Payable Property And Equipment Suppliers Current AccountsPayablePropertyAndEquipmentSuppliersCurrent	143000
CY2023Q4	plx	Accounts Payable Property And Equipment Suppliers Current AccountsPayablePropertyAndEquipmentSuppliersCurrent	614000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12271000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19550000

Files In Submission

Name	View Source	Status
0001558370-24-003161-index-headers.html	Edgar Link	pending
0001558370-24-003161-index.html	Edgar Link	pending
0001558370-24-003161.txt	Edgar Link	pending
0001558370-24-003161-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plx-20231231.xsd	Edgar Link	pending
plx-20231231x10k.htm	Edgar Link	pending
plx-20231231x10k001.jpg	Edgar Link	pending
plx-20231231x10k002.jpg	Edgar Link	pending
plx-20231231x10k003.jpg	Edgar Link	pending
plx-20231231x10k004.jpg	Edgar Link	pending
plx-20231231x10k005.jpg	Edgar Link	pending
plx-20231231x10k007.jpg	Edgar Link	pending
plx-20231231xex23d1.htm	Edgar Link	pending
plx-20231231xex23d1001.jpg	Edgar Link	pending
plx-20231231xex31d1.htm	Edgar Link	pending
plx-20231231xex31d2.htm	Edgar Link	pending
plx-20231231xex32d1.htm	Edgar Link	pending
plx-20231231xex32d2.htm	Edgar Link	pending
plx-20231231xex4d7.htm	Edgar Link	pending
plx-20231231xex97d1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
plx-20231231_cal.xml	Edgar Link	unprocessable
plx-20231231_def.xml	Edgar Link	unprocessable
plx-20231231_pre.xml	Edgar Link	unprocessable
plx-20231231x10k_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
plx-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2024 Q1 Form 10-K Financial Statement

#000155837024003161 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2024 Q1 Form 10-K Financial Statement

#000155837024003161 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx